Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wharton's jelly conditioned medium versus extracellular vesicles with IPL for rosacea
IRCT20200127046282N32Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2023
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, double-blind trial of extracellular vesicles derived from Wharton's jelly mesenchymal stem cells in rosacea (3 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Severity of rosacea lesions based on physician assessment. Started May 2023; status: completed.
02
Drugs
extracellular vesicles derived from Wharton's jelly mesenchymal stem cells
03
Conditions
rosacea
Beyond the preview
Go deeper on IRCT20200127046282N32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200127046282N32.